Indivior Pharmaceuticals, Inc.
INDV
Positions held
Your positionsINDV isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Indivior Pharmaceuticals is positioned well in the healthcare sector, focusing on specialty and generic drugs, which are increasingly in demand as healthcare systems seek cost-effective solutions.
- In Q2 2026, Indivior reported a revenue increase of 8% compared to the previous quarter, reaching $343 million.
- The operating margin expanded to 46.4% in Q2 2026, indicating improved operational efficiency.
- The company faces challenges with a negative price-to-book ratio of -20.36, indicating potential issues with asset valuation.
- In 2023, Indivior reported a net income loss of $126 million, highlighting ongoing profitability concerns.
- The gross margin decreased from 87.4% in Q1 2026 to 85.4% in Q2 2026, suggesting potential pricing pressures.
Fundamentals
| Market cap | $4.18B | Enterprise value | $4.47B | Trailing P/E | 12.71 | Forward P/E | 7.26 |
| PEG | — | Price / book | -20.11 | Beta | 1.18 | Dividend yield | 0.00% |
| Revenue growth | 13.6% | Earnings growth | 600.0% | Gross margin | 85.7% | Operating margin | 46.9% |
| Profit margin | 26.7% | ROE | — | ROA | 26.4% | Debt / equity | — |
| Current ratio | 0.84 | Free cash flow | $86.50M | Analyst recommendation | none | Mean target | $49.00 |
| 52w high | $42.81 | 52w low | $22.95 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $343M | $317M | $358M | $314M | $302M | — |
| Op margin | 46.4% | 43.2% | 23.2% | 14.0% | 23.5% | — |
| Net income | $122M | $89.0M | $102M | $42.0M | $18.0M | — |
| Gross margin | 85.4% | 87.4% | 81.3% | 73.6% | 82.8% | — |
| Gross profit | $293M | $277M | $291M | $231M | $250M | — |
| Operating income | $159M | $137M | $83.0M | $44.0M | $71.0M | — |
- Revenue +8% vs prior quarter ($343M vs $317M).
- Gross margin 85.4% (was 87.4% prior quarter).
- Operating margin expanded to 46.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.1B | $901M | — |
| Op margin | 21.4% | 19.7% | 22.6% | 23.9% | — |
| Net income | $210M | $7.0M | -$126M | -$44.0M | — |
| Gross margin | 80.1% | 80.6% | 84.1% | 83.2% | — |
| Gross profit | $993M | $957M | $919M | $750M | — |
| Operating income | $265M | $234M | $247M | $215M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-17 · Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
2026-09-14 · 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
2026-09-02 · Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
2026-08-31 · Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-08-27 · 3 Reasons Why Growth Investors Shouldn't Overlook Indivior Pharmaceuticals Inc. (INDV)
2026-08-22 · Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan
2026-08-21 · Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
2026-08-21 · Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
2026-08-03 · Indivior Q2 Earnings Call Highlights
2026-08-03 · Supernus jumps premarket on merger deal; GameStop drops
2026-08-03 · Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Price (daily)
Full chart · RSI · MACD · patterns